Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.

Autor: Bin Sawad A; Aeglea BioTherapeutics, Inc. Austin Texas USA., Pothukuchy A; Aeglea BioTherapeutics, Inc. Austin Texas USA., Badeaux M; Aeglea BioTherapeutics, Inc. Austin Texas USA., Hodson V; Aeglea BioTherapeutics, Inc. Austin Texas USA., Bubb G; Aeglea BioTherapeutics, Inc. Austin Texas USA., Lindsley K; Health Economics and Outcomes Research - Evidence Synthesis IQVIA, Inc. San Francisco California USA., Uyei J; Health Economics and Outcomes Research - Evidence Synthesis IQVIA, Inc. San Francisco California USA., Diaz GA; Division of Medical Genetics and Genomics, Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA.

Publikováno v: JIMD reports [JIMD Rep] 2022 Mar 25; Vol. 63 (4), pp. 330-340. Date of Electronic Publication: 2022 Mar 25 (Print Publication: 2022).

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.

Autor: Amoozgar Z; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Kloepper J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Ren J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Tay RE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, Boston, MA, USA., Kazer SW; Department of Chemistry, Institute for Medical Engineering & Science, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.; Ragon Institute of MGH, MIT & Harvard, Cambridge, MA, USA.; Program in Health Sciences and Technology, Harvard Medical School, Boston, MA, USA., Kiner E; Department of Immunology, Harvard Medical School, Boston, MA, USA., Krishnan S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Posada JM; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Ghosh M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Mamessier E; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Wong C; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Ferraro GB; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Batista A; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Wang N; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Badeaux M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Roberge S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Xu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Huang P; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Shalek AK; Department of Chemistry, Institute for Medical Engineering & Science, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.; Ragon Institute of MGH, MIT & Harvard, Cambridge, MA, USA.; Program in Health Sciences and Technology, Harvard Medical School, Boston, MA, USA., Fukumura D; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA., Kim HJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, Boston, MA, USA. Jain@steele.mgh.harvard.edu., Jain RK; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA. Hye-Jung_kim@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2021 May 11; Vol. 12 (1), pp. 2582. Date of Electronic Publication: 2021 May 11.

Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases.

Autor: Bian, David J. H.¹ (AUTHOR) david.bian@mail.mcgill.ca, Cohen, Sara F.² (AUTHOR) sara.cohen2@mail.mcgill.ca, Lazaratos, Anna-Maria^3,4 (AUTHOR) anna-maria.lazaratos@mail.mcgill.ca, Bouganim, Nathaniel⁵ (AUTHOR) nathaniel.bouganim@mcgill.ca, Dankner, Matthew^1,4 (AUTHOR) matthew.dankner@mail.mcgill.ca

Publikováno v: Current Oncology. Oct2024, Vol. 31 Issue 10, p6314-6342. 29p.

Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma.

Autor: Mu, Jie^1,2 (AUTHOR), Li, Ruizhi^1,3 (AUTHOR), Zheng, Yu^1,4 (AUTHOR), Lu, Yi⁴ (AUTHOR), Ma, Lei^1,3 (AUTHOR), Yin, Lin^1,3 (AUTHOR), Zhang, Miao¹ (AUTHOR), Ma, Wenyu¹ (AUTHOR), Chang, Mengjia¹ (AUTHOR), Liu, Aihua^1,2 (AUTHOR) liuah@qdu.edu.cn, Li, Jing¹ (AUTHOR) jingli@qdu.edu.cn, Zhu, Hai⁴ (AUTHOR) shijingzhou@163.com, Wang, Dong¹ (AUTHOR) dongwang@qdu.edu.cn

Publikováno v: Stem Cell Research & Therapy. 9/11/2024, Vol. 15 Issue 1, p1-16. 16p.

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.

Autor: Askoxylakis V; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Ferraro GB; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Badeaux M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Kodack DP; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Kirst I; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Shankaraiah RC; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Wong CSF; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Duda DG; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Fukumura D; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA., Jain RK; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA USA.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2019 Jan 15; Vol. 5, pp. 4. Date of Electronic Publication: 2019 Jan 15 (Print Publication: 2019).